Group 1 - The article discusses a proprietary set of indicators known as the "Beast Momentum System," which includes five core metrics: VAD, OVS, RSR, RSL, and SSV. These indicators are not commonly used and are specific to the internal workings of the "Beast" methodology [4][5]. - RSL, or Relative Strength Long, is highlighted as a key indicator that measures the long-term strength of a stock compared to the market or sector. A strong RSL indicates potential for a stock to be a "bullish candidate" [6][8]. - The article emphasizes the importance of these indicators in determining the overall market trend and identifying strong stocks, thereby providing a framework for investment decisions [5][6].

Core Viewpoint - The Hang Seng Index Company announced the inclusion of InnoCare Pharma (03696) into the Hang Seng Composite Index, effective from March 9, 2026, following a quarterly review [1] Group 1: Index Inclusion - InnoCare Pharma will be added to the Hang Seng Composite Index as part of the quarterly review results announced on February 13, 2025 [1] - The changes will be implemented after market close on March 6, 2026, and will affect the eligible stocks for the Hong Kong Stock Connect [1] - According to CICC's research report, InnoCare Pharma meets various criteria including market capitalization, liquidity, and listing duration, making it a candidate for inclusion in the Stock Connect [1] Group 2: Strategic Collaboration - On February 10, InnoCare Pharma announced a strategic collaboration with Kanghong Pharmaceutical for drug development [1] - The collaboration will focus on multiple projects in the central nervous system and autoimmune diseases, leveraging AI-enabled innovative drug development [1] - Under the agreement, InnoCare Pharma is expected to receive research funding support of up to several tens of millions of Hong Kong dollars for each project [1]

Group 1: Market Reactions - The U.S. stock market experienced significant declines, with the Dow Jones falling over 2% to close at 49,451 points, marking a drop of 669 points or 1.3% [2] - Major tech stocks saw widespread losses, including Apple down 5%, Amazon and Meta down over 2%, and Nvidia down over 1% [2] - Concerns over the impact of artificial intelligence (AI) on various industries have led to a re-evaluation of stock valuations, causing a shift towards safer assets like U.S. Treasury bonds [2][3] Group 2: Real Estate Market - U.S. existing home sales in January totaled an annualized 3.91 million units, falling short of the expected 4.15 million and marking an 8.4% month-over-month decline, the largest drop since February 2022 [3][4] - The median home price increased by 0.9% year-over-year to $396,800, but affordability remains a significant issue, with the affordability index reaching its highest level since 2022, yet still below pre-pandemic levels [4] - Economic analysts suggest that high mortgage rates and increased housing inventory will continue to suppress home price growth in the short term [4] Group 3: AI Impact on Industries - Concerns about AI disrupting traditional business models have intensified, particularly affecting sectors like software, insurance, and real estate [5][6] - The anticipated capital expenditure for AI by 2026 is projected to reach $659 billion, a 60% increase from 2025, but the growth rate is expected to slow compared to previous years [5] - The logistics and transportation sectors are facing significant sell-offs due to fears that AI will disrupt traditional freight markets, with the Russell 3000 trucking index experiencing a drop of over 9% [6][8] Group 4: Investment Trends - There is a notable shift in investment from U.S. tech stocks to emerging markets and commodities, as the market experiences a late-cycle phase characterized by internal divergence [8] - Financial assets are beginning to lose ground to physical assets, indicating a potential historical shift in investment dynamics [8]

Core Viewpoint - The stock price of CNP (CNP.N) has recently surpassed its 52-week high, reaching $41.47, indicating significant market activity and optimism from institutions [1][2]. Stock Performance - As of February 12, 2026, CNP closed at $41.47, up 1.02% for the day, breaking the previous 52-week high of $40.50 recorded on December 26, 2025. The stock has shown a steady upward trend, increasing from $38.60 on January 13, 2026, to $41.47, representing a 9.48% increase over this period. Trading activity has been robust, with a volume of 5.9948 million shares and a transaction value of $246 million on February 11, 2026 [2]. Institutional Outlook - Institutions maintain a positive outlook on CNP, with 19 firms providing insights in February 2026, of which 42% rated the stock as a buy or hold. The average target price set by these institutions is $42.71, with the highest target reaching $49.00. The company's core business remains stable, with electricity accounting for 53.11% and natural gas for 46.84% of its operations. The company has also resumed year-on-year growth in Q4 2025 [3]. Business Developments - CNP is collaborating with technology giants to develop an AI platform. The company has partnered with Palantir and NVIDIA to create new software aimed at accelerating the construction of AI data centers. This strategic collaboration is expected to enhance market expectations regarding the company's prospects in the energy digitalization sector [4].

Core Insights - A new study from Harvard Business Review indicates that the adoption of AI by companies may raise expectations and extend working hours, leading to increased fatigue among employers and a higher risk of employee turnover [1][2]. Group 1 - The implementation of AI platforms, such as those from Microsoft, is associated with heightened employer fatigue [1][2]. - Companies investing in AI may face an increased risk of employee attrition due to extended working hours and elevated expectations [1][2].

Core Viewpoint - The collaboration between 英矽智能 (Insilico Medicine) and 康哲药业 (Kanghong Pharmaceutical) in AI-driven drug development for central nervous system and autoimmune diseases is expected to enhance innovation and research capabilities in the pharmaceutical industry [1] Group 1: Company Developments - 英矽智能's stock price increased by over 9% to 73.45 HKD, reaching a new high of 74.80 HKD during trading [1] - The company is set to receive up to tens of millions of HKD in research funding for each of the projects under the collaboration agreement with 康哲药业 [1] Group 2: Industry Insights - 大摩 (Morgan Stanley) highlighted 英矽智能 as a leader in the AIDD (AI-Driven Drug Development) field, noting significant progress in both technology validation and application [1] - The execution capability of 英矽智能's chemical models supports a repeatable "1-to-N" innovation creation engine, with potential for further growth as biological model validations become evident [1]

Core Viewpoint - The company, 英硅智能, has announced a strategic collaboration with 康哲药业 for drug development, focusing on AI-powered innovative drug research in the central nervous system and autoimmune diseases [1] Group 1: Collaboration Details - The partnership will leverage 英硅智能's validated AI platform and innovative drug development capabilities alongside 康哲药业's experienced research team and deep understanding of disease areas [1] - The agreement stipulates the joint development of at least two research projects [1] Group 2: Financial Aspects - 英硅智能 is expected to receive up to several tens of millions of Hong Kong dollars in research funding for each project [1]

Core Viewpoint - The first legal case in China regarding AI "hallucination" has been ruled, highlighting the need to clarify responsibility for AI-generated errors and the implications for AI governance [1][2] Group 1: Case Summary - A high school student's relative discovered inaccuracies in information generated by an AI platform and sued the company for compensation after the AI suggested it would pay 100,000 yuan for errors [1] - The Hangzhou Internet Court dismissed the lawsuit, indicating that AI outputs are probabilistic and do not constitute legally binding commitments [2] Group 2: Legal Implications - The court's ruling emphasizes that AI does not bear absolute responsibility for its outputs, but AI operators must fulfill governance responsibilities and reasonable care obligations [2] - The judgment shifts the focus from "result guarantee" to "risk control," assessing whether service providers meet obligations for warnings, corrections, and safety evaluations [2] Group 3: Risks of AI "Hallucination" - AI "hallucination" is recognized as a significant risk in AI usage, with examples emerging globally, such as a lawsuit against the AI chatbot Grok for providing misleading information [3] - The severity of risks associated with AI "hallucination" is closely linked to the application context, with potential serious consequences in critical areas like legal judgments and medical diagnoses [3] Group 4: Governance Exploration - The challenges posed by AI "hallucination" are likened to historical issues such as information silos and digital divides, suggesting a need for a nuanced understanding of the problem [4] - Emphasizing the importance of continued use and training of AI technologies to improve their reliability and service to humanity, rather than abandoning them due to current limitations [4]

Core Insights - The integration of AI in the proofreading of ancient texts is significantly enhancing efficiency, allowing for the collaboration of thousands of university students and volunteers [1][2] - AI serves as a "digital key" that revitalizes traditional culture, enabling the preservation and transmission of ancient wisdom in a modern context [1][2] Group 1: AI's Role in Cultural Preservation - AI is transforming the proofreading process of ancient texts like the "Yongle Dadian" and the "Kangxi Dictionary," increasing efficiency by several times compared to traditional methods [1] - The historical reliance on manual labor for ancient text organization has been improved with AI, which addresses the slow speed and errors associated with earlier computer text entry methods [1] Group 2: Human-AI Collaboration - While AI enhances efficiency, it is not infallible; experts are still needed to verify rare characters and special contexts, highlighting the importance of human oversight [1] - The collaboration between AI and humans allows individuals to focus on deeper interpretation and creative transformation of cultural content, representing an ideal state of "human-machine collaboration" [1]

Core Viewpoint - The article discusses the phenomenon of "AI hallucination," where AI generates incorrect information, and the implications for AI service providers regarding liability and user trust [1][6]. Group 1: AI Hallucination Phenomenon - AI operates as a "probability calculator," generating responses based on patterns in training data rather than true understanding [1][2]. - The limitations of training data can lead to inaccuracies; even a small percentage of errors in the data can significantly increase the error output rate [2]. - AI tends to exhibit a "people-pleasing" behavior, fabricating plausible answers when uncertain, rather than admitting a lack of knowledge [3][4]. Group 2: Legal Responsibilities of AI Providers - AI service providers have a strict obligation to review content for harmful or illegal information and must inform users about the inherent limitations of AI-generated content [7]. - The court ruled that the defendant had fulfilled their obligations by providing clear warnings about the limitations of AI-generated content and employing techniques to enhance output reliability [8]. Group 3: Reducing AI Hallucination - To minimize AI hallucination, users should optimize their questions by being specific and providing context, which can lead to more accurate responses [9]. - Limiting the amount of content generated at once can reduce the likelihood of hallucinations, suggesting a step-by-step approach to content creation [9]. - Cross-validation by querying multiple AI models can enhance the reliability of the answers received [9].